Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677344 | 1.00 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL7470872 | 0.85 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL19615983 | 0.85 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL11462597 | 0.82 | KDM4C (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL21761435 | 0.82 | KDM4C (0.41) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL13480700 | 0.82 | KDM4C (0.41) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL26666712 | 0.81 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL10463692 | 0.81 | MEN1 (0.38) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL12153137 | 0.81 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL12153132 | 0.81 | NPC1 (0.34) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988397-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170267695-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| US-20140249105-A1 | NOVEL CERAMIDE ANALOGUES, PROCESSES FOR PREPARING SAME AND USES THEREOF | DIVERCHIM (FR) | 2014-09-04 | — | — | US | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| US-20070066580-A1 | Novel aldosterone antagonists and uses thereof | RECORDATI IRELAND LIMITED (IE) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | MEN1 3792/4885KMT2A 3692/4885KDM4C 4629/4885 |
| US-20170267695-A1 | ERK INHIBITORS | MAPK1, MAP3K1, MAPK4 | MEN1 1248/4885KMT2A 1567/4885KDM4C 2181/4885 |
| US-20140249105-A1 | NOVEL CERAMIDE ANALOGUES, PROCESSES FOR PREPARING SAME AND USES THEREOF | CERS2, CERT1, SGMS2 | MEN1 1458/4885KMT2A 3589/4885KDM4C 2769/4885 |
| US-20070066580-A1 | Novel aldosterone antagonists and uses thereof | NR3C2, REN, AGTR2 | MEN1 1573/4885KMT2A 3681/4885KDM4C 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.